Capital Com MENA Securities Trading LLC is regulated by the Capital Market Authority.
Open platformOpen platform

NewAmsterdam Pharma Q3 2026 net loss narrows 76% year over year to USD 17.39 million

By Public Technologies
  • NewAmsterdam Pharma’s third-quarter 2026 net loss narrowed 76% year over year to $17.39 million.
  • Revenue rose to $19.16 million from a year earlier, primarily due to regulatory milestones under the Menarini license agreement.
  • Cash, cash equivalents and marketable securities totaled $643.1 million at September 30, 2026.
  • European Commission marketing authorizations for Ubeslo and Evlarco marked obicetrapib’s first regulatory approval worldwide.
  • The PREVAIL interim analysis is planned for fourth-quarter 2026, with results expected in first-quarter 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NewAmsterdam Pharma Company NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611040730PRIMZONEFULLFEED9869787) on November 04, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.